Preliminary data from the first trial of a Zika virus (ZIKV) vaccine in human subjects, ZIKA-001, show that three doses of the synthetic GLS-5700 DNA vaccine led to binding antibody production in all subjects and neutralizing antibodies in more than half of samples tested, researchers reported in an article published online October 4 in the New England Journal of Medicine.